NIIMBL Announces 2026 eXperience Request for Applications & eXperience Day Request for Information; Listening Session scheduled for May 22

NIIMBL is pleased to announce the 2026 NIIMBL eXperience Request for Applications and eXperience Day Request for Information.
NIIMBL Announces 11 New Technology, Workforce, and Global Health Fund Projects
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 11 new member-led technology, workforce development, and Global Health Fund projects with a value of ~$11.2 million through the Institute’s Project Call 8.1.
Government Leaders Call for Expanded Biotech Workforce Development, Private-Public Partnerships to Unleash Biotechnology Innovation

The National Security Commission on Emerging Biotechnology (NSCEB), along with Senator Coons and Representative McBride, visited NIIMBL to see how government & industry partnerships drive innovation and workforce development.
NIIMBL Announces RFA for Optimizing Long-read Next Sequencing Capabilities

NEWARK, Del., March 4, 2025 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce a Request for Applications (RFA) to participate in its Viral Vector Program’s initiative on optimizing long-read next generation sequencing (NGS) capabilities. With the emergence of gene therapies as a treatment option for a variety of health […]
NIIMBL is accepting applications for the 2025 eXperience

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce student applications for the 2025 NIIMBL eXperience are now open. Students can apply to one of seven unique programs across the U.S.
NIIMBL Awards $600K for 7 eXperience Programs in 2025

NIIMBL is pleased to announce it has awarded $600K to launch seven NIIMBL eXperience programs in regions throughout the United States during the summer of 2025. Each location will host a week-long program, designed to foster diversity within the biopharmaceutical industry and introduce first- and second-year college students to new career possibilities.
NIIMBL Announces Up To $4M Available for Technology and Workforce and $1.7M for Global Health Fund Projects

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce Project Call 8.1 for Technology, Workforce Development, and Global Health Fund projects.
NIIMBL announces 2 RFIs focused on data connectivity and federated learning for biopharmaceutical manufacturing

NIIMBL is pleased to announce two Requests for Information (RFI) related to universal connectivity and federated learning as part of the Institute’s Big Data Program.
NIIMBL and Open Applications Group (OAGi) partner to develop open-source biopharmaceutical manufacturing ontologies

NIIMBL has contributed biopharmaceutical manufacturing ontologies to The Open Applications Group (OAGi) for further development as an open-source project.
NIIMBL collaborates on review of vaccine process technology developments

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has published “Vaccine process technology—a decade of progress” in Biotechnology and Bioengineering. The paper serves as an update to a 2012 review titled “Vaccine process technology” authored by NIIMBL Executive Director Barry Buckland and explores transformations in vaccine development over the past decade.
NIIMBL announces 63 students for the 2024 NIIMBL eXperience

The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce 63 students from 41 academic institutions have been selected to take part in the 2024 NIIMBL eXperience
NIIMBL Announces $10M for 8 New Biopharmaceutical Manufacturing Projects

NEWARK, Del., April 9, 2024 — The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) is pleased to announce approximately $10M in planned project activities through the Institute’s Project Call 7.1 for eight new technology and workforce development projects that will help address key opportunities for innovation in biopharmaceutical manufacturing.